218 related articles for article (PubMed ID: 25666181)
21. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
[TBL] [Abstract][Full Text] [Related]
22. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
Beaulieu PL
Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
[TBL] [Abstract][Full Text] [Related]
23. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
Wu JZ; Yao N; Walker M; Hong Z
Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
[TBL] [Abstract][Full Text] [Related]
26. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
[TBL] [Abstract][Full Text] [Related]
27. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
28. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
[TBL] [Abstract][Full Text] [Related]
29. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
Ma R; Wang P; Wu J; Ruan K
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
[TBL] [Abstract][Full Text] [Related]
31. Direct-acting and host-targeting HCV inhibitors: current and future directions.
Chatel-Chaix L; Germain MA; Götte M; Lamarre D
Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
[TBL] [Abstract][Full Text] [Related]
32. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase.
Zheng BZ; D'Andrea SV; Hanumegowda U; Knipe JO; Mosure K; Zhuo X; Lemm JA; Liu M; Rigat KL; Wang YK; Fang H; Poronsky C; Cutrone J; Wu DR; Arunachalam PN; Balapragalathan TJ; Arumugam A; Mathur A; Meanwell NA; Gao M; Roberts SB; Kadow JF
Bioorg Med Chem Lett; 2017 Aug; 27(15):3294-3300. PubMed ID: 28633899
[TBL] [Abstract][Full Text] [Related]
33. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
[TBL] [Abstract][Full Text] [Related]
35. A novel hepatitis C virus NS5B polymerase assay of de novo initiated RNA synthesis directed from a heteropolymeric RNA template.
Ferrari E; Huang HC
Methods Mol Biol; 2013; 1030():81-92. PubMed ID: 23821261
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.
Rosnoblet C; Fritzinger B; Legrand D; Launay H; Wieruszeski JM; Lippens G; Hanoulle X
J Biol Chem; 2012 Dec; 287(53):44249-60. PubMed ID: 23152499
[TBL] [Abstract][Full Text] [Related]
37. A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A.
Ranjith-Kumar CT; Wen Y; Baxter N; Bhardwaj K; Cheng Kao C
PLoS One; 2011; 6(7):e22575. PubMed ID: 21799903
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
[TBL] [Abstract][Full Text] [Related]
39. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.
Rai R; Deval J
Antiviral Res; 2011 May; 90(2):93-101. PubMed ID: 21295075
[TBL] [Abstract][Full Text] [Related]
40. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.
Nyanguile O; Devogelaere B; Vijgen L; Van den Broeck W; Pauwels F; Cummings MD; De Bondt HL; Vos AM; Berke JM; Lenz O; Vandercruyssen G; Vermeiren K; Mostmans W; Dehertogh P; Delouvroy F; Vendeville S; VanDyck K; Dockx K; Cleiren E; Raboisson P; Simmen KA; Fanning GC
J Virol; 2010 Mar; 84(6):2923-34. PubMed ID: 20071590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
